Entity Common Stock, Shares Outstanding of Aptevo Therapeutics Inc. from 01 Aug 2016 to 06 Nov 2025

Taxonomy & unit
dei: shares
Description
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
Summary
Aptevo Therapeutics Inc. quarterly Entity Common Stock, Shares Outstanding in shares history and change rate from 01 Aug 2016 to 06 Nov 2025.
  • Aptevo Therapeutics Inc. Entity Common Stock, Shares Outstanding for the quarter ending 06 Nov 2025 was 16,850,494, a 9% decline year-over-year.
Source SEC data
View on sec.gov
Entity Common Stock, Shares Outstanding, Quarterly (shares)
Entity Common Stock, Shares Outstanding, YoY Quarterly Change (%)

Aptevo Therapeutics Inc. Quarterly Entity Common Stock, Shares Outstanding (shares)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 16,850,494 -1,661,590 -9% 06 Nov 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 3,287,918 -6,132,571 -65% 11 Aug 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 8,109,290 -15,363,146 -65% 15 May 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 1,458,445 14 Feb 2025 10-K 14 Feb 2025 2024 FY
Q3 2024 18,512,084 +895,312 +5.1% 07 Nov 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 9,420,489 -2,103,227 -18% 08 Aug 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 23,472,436 +16,232,965 +224% 05 Mar 2024 10-K 05 Mar 2024 2023 FY
Q3 2023 17,616,772 +12,525,014 +246% 14 Nov 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 11,523,716 +6,433,072 +126% 10 Aug 2023 10-Q 10 Aug 2023 2023 Q2
Q1 2023 7,239,471 +2,232,230 +45% 30 Mar 2023 10-K 30 Mar 2023 2022 FY
Q3 2022 5,091,758 +193,724 +4% 10 Nov 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 5,090,644 +196,653 +4% 11 Aug 2022 10-Q 11 Aug 2022 2022 Q2
Q1 2022 5,007,241 +557,819 +13% 24 Mar 2022 10-K 24 Mar 2022 2021 FY
Q3 2021 4,898,034 +753,023 +18% 11 Nov 2021 10-Q 12 Nov 2021 2021 Q3
Q2 2021 4,893,991 +1,661,180 +51% 11 Aug 2021 10-Q 12 Aug 2021 2021 Q2
Q1 2021 4,449,422 -40,829,822 -90% 31 Mar 2021 10-K 31 Mar 2021 2020 FY
Q3 2020 4,145,011 -41,134,233 -91% 10 Nov 2020 10-Q 10 Nov 2020 2020 Q3
Q2 2020 3,232,811 -41,866,012 -93% 14 Aug 2020 10-Q 14 Aug 2020 2020 Q2
Q1 2020 45,279,244 +2,339,025 +5.4% 25 Mar 2020 10-K 25 Mar 2020 2019 FY
Q3 2019 45,279,244 +22,591,390 +100% 06 Nov 2019 10-Q 07 Nov 2019 2019 Q3
Q2 2019 45,098,823 +22,429,418 +99% 06 Aug 2019 10-Q 09 Aug 2019 2019 Q2
Q1 2019 42,940,219 +21,827,614 +103% 14 Mar 2019 10-K 18 Mar 2019 2018 FY
Q3 2018 22,687,854 +1,259,386 +5.9% 09 Nov 2018 10-Q 14 Nov 2018 2018 Q3
Q2 2018 22,669,405 +1,250,049 +5.8% 07 Aug 2018 10-Q 09 Aug 2018 2018 Q2
Q1 2018 21,112,605 +194,315 +0.93% 09 Mar 2018 10-K 13 Mar 2018 2017 FY
Q3 2017 21,428,468 +1,179,644 +5.8% 06 Nov 2017 10-Q 13 Nov 2017 2017 Q3
Q2 2017 21,419,356 +1,189,507 +5.9% 08 Aug 2017 10-Q 10 Aug 2017 2017 Q2
Q1 2017 20,918,290 24 Mar 2017 10-K 31 Mar 2017 2016 FY
Q3 2016 20,248,824 01 Nov 2016 10-Q 14 Nov 2016 2016 Q3
Q2 2016 20,229,849 01 Aug 2016 10-Q/A 22 Sep 2016 2016 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.